1. Home
  2. PNNT vs AUTL Comparison

PNNT vs AUTL Comparison

Compare PNNT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PennantPark Investment Corporation

PNNT

PennantPark Investment Corporation

HOLD

Current Price

$4.60

Market Cap

285.3M

Sector

Finance

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.47

Market Cap

431.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNNT
AUTL
Founded
2007
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
285.3M
431.2M
IPO Year
2007
2025

Fundamental Metrics

Financial Performance
Metric
PNNT
AUTL
Price
$4.60
$1.47
Analyst Decision
Hold
Strong Buy
Analyst Count
5
4
Target Price
$5.85
$8.50
AVG Volume (30 Days)
747.6K
1.7M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
20.87%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
N/A
$84.74
Revenue Next Year
N/A
$65.76
P/E Ratio
$13.14
N/A
Revenue Growth
N/A
496.00
52 Week Low
$4.29
$1.15
52 Week High
$7.53
$2.70

Technical Indicators

Market Signals
Indicator
PNNT
AUTL
Relative Strength Index (RSI) 47.10 52.78
Support Level N/A $1.45
Resistance Level $4.69 $1.52
Average True Range (ATR) 0.13 0.08
MACD 0.04 0.02
Stochastic Oscillator 77.25 74.07

Price Performance

Historical Comparison
PNNT
AUTL

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Share on Social Networks: